Glenmark Pharmaceuticals, the Mumbai-based drug firm, launched an antiviral drug, Fabiflu on Saturday for treating patients of coronavirus with mild to moderate symptoms.
FabiFlu is the first oral Favipiravir-approved medication for the treatment of Covid-19, the company said in a statement, reports Business Insider.
The firm had received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) on Friday.
“This approval comes at a time when cases in India are spiraling like never before, putting a tremendous pressure on our healthcare system,” Glenmark Pharmaceuticals Chairman and Managing Director Glen Saldanha said.
He added that the availability of an effective treatment such as Fabiflu might help to ease the pressure on the system by offering patients in India a much-needed therapy option.
Coronavirus has thus far infected 412,210 people and killed 13,285 people in India, according to Worldometer.
